NICE criteria thresholds for recommending PCSK9i therapy in patients with persistent hypercholesterolaemia13 14
| Patients | Without CVD | With CVD | |
| High risk of CVD* | Very high risk of CVD†| ||
| Primary non-FH or mixed dyslipidaemia | Not recommended at any LDL-C concentration | Recommended only if LDL-C persistently >4.0 mmol/L | Recommended only if LDL-C persistently >3.5 mmol/L |
| Primary heterozygous FH | Recommended only if LDL-C persistently >5.0 mmol/L | Recommended only if LDL-C persistently >3.5 mmol/L | |
*A history of any of the following: acute coronary syndrome (such as myocardial infarction or unstable angina needing hospitalisation); coronary or other arterial revascularisation procedures; chronic heart disease; ischaemic stroke; or peripheral arterial disease.
†Recurrent cardiovascular events or cardiovascular events in >1 vascular bed.
CVD, cardiovascular disease; FH, familial hypercholesterolaemia; LDL-C, low-density lipoprotein-cholesterol; NICE, National Institute for Health and Care Excellence; PCSK9i, proprotein convertase subtilisin/kexin type 9 inhibitor.